Literature DB >> 4087169

Fractions metabolized in a triangular metabolic system: cinromide and two metabolites in the rhesus monkey.

E A Lane, R H Levy.   

Abstract

A previous study of the metabolic fate of cinromide (3-bromo-N-ethylcinnamamide) in rhesus monkey established that half of a dose is metabolized by N-deethylation to an active metabolite, 3-bromocinnamamide. Both cinromide and its proximal metabolite can be metabolized by amide hydrolysis to a second metabolite, 3-bromocinnamic acid, resulting in a triangular metabolic problem. This investigation was undertaken to distinguish between these two nonexclusive possibilites. A preliminary study was carried out to characterize the pharmacokinetics of 3-bromocinnamic acid. In the main study, six monkeys received an intravenous dose of cinromide, 3-bromocinnamamide, and 3-bromocinnamic acid in a randomized order. The time courses of compound administered and corresponding metabolites were followed. The following fractions of dose metabolized (mean +/- SD) were obtained: cinromide to 3-bromocinnamide: 0.53 +/- 0.24; 3-bromocinnamamide to 3-bromocinnamic acid: 0.53 +/- 0.21; cinromide to 3-bromocinnamic acid directly: 0.48 +/- 0.32. Thus, it was found that 3-bromocinnamic acid is formed directly from cinromide and from 3-bromocinnamamide. Also, as primary metabolites, 3-bromocinnamic acid and 3-bromocinamamide account for all of a cinromide dose with a mean value of 1.00 +/- 0.34. The observed variability in these fractions metabolized was explained by the fact that in the solution of the triangular metabolic problem, three clearances are assumed to remain constant over three studies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4087169     DOI: 10.1007/BF01061475

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  13 in total

1.  A commentary: methods and assumptions in the kinetic estimation of metabolite formation.

Authors:  K S Pang; K C Kwan
Journal:  Drug Metab Dispos       Date:  1983 Mar-Apr       Impact factor: 3.922

2.  In vivo evaluation of the Michaelis-Menten constant for a medium extraction ratio drug: application to cinromide in the rhesus monkey.

Authors:  E A Lane; R H Levy
Journal:  J Pharm Sci       Date:  1983-11       Impact factor: 3.534

3.  Enzyme induction following a single dose of amobarbital in dogs.

Authors:  P A Reilly; T Inaba; D Kadar; L Endrenyi
Journal:  J Pharmacokinet Biopharm       Date:  1978-08

4.  Metabolite pharmacokinetics: the area under the curve of metabolite and the fractional rate of metabolism of a drug after different routes of administration for renally and hepatically cleared drugs and metabolites.

Authors:  K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

5.  Experimental anticonvulsant cinromide in monkey model: preliminary efficacy.

Authors:  J S Lockard; R H Levy; L L DuCharme; W C Congdon
Journal:  Epilepsia       Date:  1979-08       Impact factor: 5.864

6.  Sequential first-pass elimination of a metabolite derived from a precursor.

Authors:  K S Pang; J R Gillette
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

7.  Cinromide's metabolite in monkey model: gastric administration and seizure control.

Authors:  J S Lockard; R H Levy; L L DuCharme; W C Congdon
Journal:  Epilepsia       Date:  1980-04       Impact factor: 5.864

8.  Pharmacokinetic relationships between cinromide and its metabolites in the rhesus monkey I: 3-Bromocinnamamide, an active metabolite.

Authors:  E A Lane; R H Levy
Journal:  J Pharm Sci       Date:  1983-05       Impact factor: 3.534

9.  Differential kinetics of cinromide and two of its metabolites in epileptic patients.

Authors:  A J Wilensky; E A Lane; R H Levy; L M Ojemann; P N Friel
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Quantitation of the anticonvulsant cinromide (3-bromo-N-ethylcinnamamide) and its major plasma metabolites by thin-layer chromatography.

Authors:  R L DeAngelis; M M Robinson; A R Brown; T E Johnson; R M Welch
Journal:  J Chromatogr       Date:  1980-12-12
View more
  2 in total

1.  Primary, secondary, and tertiary metabolite kinetics.

Authors:  M V St-Pierre; X Xu; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1988-10

2.  Pharmacokinetics of a nootropic agent, BMY-21502, and its metabolites in beagle dogs.

Authors:  N Srinivas; S Kaul
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.